B
BioVascular
Biovascular is dedicated to developing new ways to treat cardiovascular conditions
About BioVascular
BioVascular Inc. is a privately held biotechnology company focused on developing and commercializing novel cardiovascular therapeutics to address significant unmet medical needs. The company operates in the biotechnology and pharmaceutical market, primarily targeting cardiovascular diseases. BioVascular's lead product, Saratin, is a polypeptide produced through recombinant means in yeast, licensed from Merck, KGaA in 2005. Saratin is designed to reduce intimal hyperplasia, a condition associated with vascular procedures, and mitigate cardiovascular risk factors. The company began human clinical trials of Saratin for hemodialysis graft access in late 2006 and plans to extend trials to peripheral artery grafts. BioVascular serves healthcare providers, particularly those specializing in cardiovascular treatments, and aims to improve patient outcomes through innovative drug and device solutions. The business model revolves around the development, clinical testing, and commercialization of its proprietary therapeutics, generating revenue through product sales and potential licensing agreements.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2006
- Headquarters
- San Diego, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 22.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Feb 2008 | $11M | $44M | BB Biotech Ventures · Domain Associates | — |
Growth signals
Latest recorded traffic for BioVascular is 30 monthly website visits. BioVascular's team declined 66.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
- BVBB Biotech Ventures
Domain Associates
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioVascular on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioVascular’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.